Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple sclerosis

Showing 15 posts of 105 posts found.

teva_copy

Teva hit by patent blow upon top-selling MS drug

January 31, 2017
Manufacturing and Production Mylan, Teva, generic, multiple sclerosis

Teva endured a rough ride in 2016, seeing its market value sink progressively over the course of the year. It …

News
biogen_austria_238

Biogen shells out $1.25bn to protect best-selling MS drug

January 18, 2017
Research and Development, Sales and Marketing Biogen, Forward Pharma, multiple sclerosis, tecfidera

Biogen has announced it is to pay $1.25 billion to Copenhagen-based biotech Forward Pharma in the latest development in a …

News
roche__tree

Roche’s ground-breaking MS drug delayed by manufacturing issues

December 22, 2016
Genentech, MS, Roche, multiple sclerosis

Roche has released both good and bad news just before Christmas. The good news is very good news for individuals …

News
shutterstock_38078521

Apitope reclaims multiple sclerosis treatment from Merck after 7 years

October 17, 2016
Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis

Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …

News
images

Roche’s Ocrevus more effective than Merck’s Rebif, company claims

September 14, 2016
Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …

News
novartis_malaria_researcher

Positive Phase III results for Novartis MS drug

August 25, 2016
Research and Development Novartis, multiple sclerosis, phase III

Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …

News
teva_copy

Teva loses patent protection on lucrative MS treatment

August 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …

News
logo_400x400

Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis

July 7, 2016
Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta

Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …

News

Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation

Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …

News
lab

New high-risk treatment can halt MS, claim researchers

June 10, 2016
Research and Development multiple sclerosis, research

The results of a Phase II clinical trial, published in The Lancet, suggests that a new use of chemotherapy followed …

News
biogen_austria_238

Biogen MS drug misses primary endpoint in Phase II trial

June 8, 2016
Research and Development Biogen, MS, multiple sclerosis, opicinumab

Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …

News
clinical_trial_4

Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016
Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …

News
biogen_idec_hillerod_2008

Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …

News
whats_up_doc

Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

April 20, 2016
Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …

News
microsoft_novartis_kinect

Novartis and Microsoft team up for Kinect collab

March 8, 2016
Manufacturing and Production, Research and Development Microsoft, Novartis, multiple sclerosis

Novartis has partnered with technology giant Microsoft; hoping to use its Kinect motion sensor to quantify whether its multiple sclerosis …

Feature

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024